Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,981 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Body mass index at birth and early life and colorectal cancer: A two-sample Mendelian randomization analysis in European and East Asian genetic similarity populations.
Papadimitriou N, Murphy N, Jenab M, Chen Z, Brenner H, Kweon SS, Le Marchand L, Moreno V, Platz EA, van Duijnhoven FJB, Cheng I, Pai RK, Phipps AI, Peters U, Zheng W, Hughes DJ. Papadimitriou N, et al. Among authors: hughes dj. Pediatr Obes. 2024 Nov 25:e13186. doi: 10.1111/ijpo.13186. Online ahead of print. Pediatr Obes. 2024. PMID: 39587448
Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials.
Díaz-Manera J, Hughes D, Erdem-Özdamar S, Tard C, Béhin A, Bouhour F, Davison J, Hahn SH, Haack KA, Huynh-Ba O, Periquet M, Tammireddy S, Thibault N, Zhou T, van der Ploeg AT. Díaz-Manera J, et al. Among authors: hughes d. Mol Genet Metab. 2024 Nov 8;143(4):108608. doi: 10.1016/j.ymgme.2024.108608. Online ahead of print. Mol Genet Metab. 2024. PMID: 39566417 Free article.
Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections.
Hernández-Lozano I, Aranzana-Climent V, Cao S, Matias C, Ulf Hansen J, Liepinsh E, Hughes D, Hobbie SN, Vingsbo Lundberg C, Friberg LE. Hernández-Lozano I, et al. Among authors: hughes d. J Antimicrob Chemother. 2024 Nov 16:dkae409. doi: 10.1093/jac/dkae409. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39548844
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Kishnani PS, Byrne BJ, Claeys KG, Díaz-Manera J, Dimachkie MM, Kushlaf H, Mozaffar T, Roberts M, Schoser B, Hummel N, Kopiec A, Holdbrook F, Shohet S, Toscano A; PROPEL Study Group. Kishnani PS, et al. J Patient Rep Outcomes. 2024 Nov 13;8(1):132. doi: 10.1186/s41687-024-00805-w. J Patient Rep Outcomes. 2024. PMID: 39535661 Free PMC article. Clinical Trial.
3,981 results